Engflag

Uprise-D3

Quick links to important sections

Uprise-D3

Uprise-D3_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uprise-D3

Property Description
Active Ingredient Cholecalciferol (Vitamin D3)
Form Oral (typically softgel capsules or tablets)
Pharmacological Class Fat-soluble vitamin / Prohormone
Common Use Maintaining calcium and phosphate balance
Origin Biologically preferred form, identical to that made in skin via sun exposure

Uprise-D3: Essential Identity and Active Substance

Uprise-D3 is a widely used health product containing the active substance cholecalciferol, the chemical name for Vitamin D3. It is classified as a fat-soluble vitamin that acts as a prohormone, crucial for regulatory processes in the body. Uprise-D3 is primarily offered in an oral capsule format, which provides a precise, standardized dose. The capsule formulation is designed to suspend the cholecalciferol in an oil base to enhance the vitamin's reliable absorption in the gut.

The Difference Between Vitamin D3 and D2

Uprise-D3 is defined by its use of Vitamin D3 (cholecalciferol), which is biologically identical to the vitamin that the body naturally produces through sun exposure. This form is favored over Vitamin D2 (ergocalciferol) for effectively raising and sustaining adequate Vitamin D levels in the blood. Using the D3 form positions Uprise-D3 as a supplement that provides the vitamin in the most bioavailable and metabolically preferred structure for human physiology.

General Role: Why Vitamin D is Fundamental to Health

The core function of the cholecalciferol in Uprise-D3 is to act as an essential bodily regulator. Its main role is to manage the absorption of calcium and phosphate from the diet, which are vital for numerous systems. This regulatory action is foundational for supporting skeletal integrity and muscle function. A common scenario for its use is supplementing individuals whose dietary intake or sun exposure is insufficient to meet their body's required vitamin levels, thereby ensuring general physiological well-being.

Regulatory References

  1. Cholecalciferol (Vitamin D3)
  2. Fat-Soluble Vitamins
  3. MedlinePlus, Cholecalciferol
  4. Vitamin D

What side effects are possible with Uprise-D3?

Possible Side Effects and Safety Information

The safety profile of cholecalciferol (Vitamin D3), the active ingredient in Uprise-D3, is primarily defined by the risk of excessive calcium levels in the body, which typically occurs with over-ingestion leading to toxicity, not standard therapeutic use. Regulatory documents classify potential adverse reactions based on frequency and affected body systems.

Officially Documented Adverse Reactions

The most significant safety concerns are linked to hypercalcemia (high blood calcium) and hypercalciuria (high urinary calcium), which are classified as uncommon effects. These are the main manifestations of excessive Vitamin D intake and are monitored for safety.

  • Uncommon Reactions (Affecting 1 in 100 to 1 in 1,000 people): Hypercalcemia, Hypercalciuria.
  • Rare Reactions (Affecting 1 in 1,000 to 1 in 10,000 people): Hypersensitivity reactions (e.g., rash, pruritus, or hives).

Affected System-Organ Classes

Adverse effects listed in official labeling are grouped by the physiological system involved:

System-Organ Class Key Adverse Reaction Type
Metabolism and Nutrition Hypercalcemia
Gastrointestinal Disorders Nausea, vomiting, constipation, flatulence
Renal and Urinary Disorders Hypercalciuria, potential for Nephrocalcinosis

Serious Safety Considerations

Severe adverse reactions documented in regulatory sources are consequences of profound and prolonged hypercalcemia, which can potentially lead to irreversible renal impairment or nephrocalcinosis (calcification of the renal tissue).

Safety Restrictions: The medication is formally contraindicated and should not be used in individuals with pre-existing hypercalcemia, hypercalciuria, or any current evidence of Vitamin D toxicity, as stated in official product labeling.

Overdose and Emergency Response

The official regulatory profile for Uprise-D3 (Cholecalciferol) overdose is defined by the toxic state known as Hypervitaminosis D, which leads to the critical physiological finding of hypercalcemia (excess calcium in the blood), hyperphosphatemia, and hypercalciuria.

Documented Manifestations and Severe Outcomes

Overdose manifestations documented in regulatory sources include gastrointestinal symptoms such as persistent nausea, vomiting, abdominal pain, and constipation. Systemic signs are polydipsia (increased thirst), polyuria (frequent urination), fatigue, and muscle weakness. Neuropsychiatric effects, such as confusion and lethargy, are also noted.

Severe or life-threatening outcomes include irreversible renal impairment, soft tissue calcification, cardiac arrhythmias (heart rhythm disturbances), and coma. Regulatory documents specify that overdose severity is heightened in patients with pre-existing renal impairment.

Required Emergency Action

Official prescribing information mandates that individuals exhibiting symptoms of high Vitamin D levels seek immediate medical attention or emergency attention for progressive, severe hypercalcemia. Management requires the immediate discontinuation of the medication and any concurrent calcium supplements. No specific antidote exists for cholecalciferol toxicity; treatment is strictly supportive and symptomatic, focused on restoring hydration and lowering calcium levels. Rigorous monitoring of serum and urinary calcium levels, as well as renal function, is required.

Therapeutic Uses of Uprise-D3

What Uprise-D3 Treats: Main Uses and Benefits

This medication is used to treat diagnosed Vitamin D deficiency and insufficiency, which is often associated with specific bone diseases. It is relevant in providing supportive relief for conditions such as Osteomalacia in adults and Rickets in children, and is relevant in settings marked by temporary physiological imbalance. Managing this deficiency may help support a stable disease course and supports the maintenance of skeletal stability. The medication is commonly used to help manage the symptoms associated with: bone pain, muscle weakness, and chronic fatigue.

“Uprise-D3 is commonly used as a supportive measure in older adults and postmenopausal women to address low bone density and the risk of fragility fractures.”

Easing Musculoskeletal Discomfort and Functional Weakness

This medication is applied to manage symptomatic patterns linked to chronic deficiency, particularly persistent bone tenderness and generalized muscle aches. Applied across domains where additional symptomatic support is needed, Uprise-D3 provides support that helps ease the overall symptom burden related to the musculoskeletal system and may assist with managing chronic fatigue symptoms that interfere with daily functioning. Its use is relevant for managing conditions that require support for bone mineralization and overall skeletal health, which assists with maintaining functional stability.

Quick Fact: Support for Deficiency-Related Fatigue Uprise-D3 is commonly used to help manage systemic symptoms like fatigue and weakness that are associated with chronic Vitamin D insufficiency, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview of Cholecalciferol

Eligibility and Restrictions for Use

The eligibility profile for Uprise-D3 (Cholecalciferol) is strictly defined by specific physiological and demographic criteria documented in official regulatory labeling. Use is typically approved for adults and the elderly, and for adolescents from 12 years of age under medical supervision.

Exclusion Rules (Contraindications)

The medicine is contraindicated and must not be used in patients diagnosed with:

  • Hypercalcaemia or Hypercalciuria (excessive calcium in blood or urine).
  • Hypervitaminosis D (pre-existing high Vitamin D levels).
  • Severe renal impairment (kidney dysfunction).
  • Calcium nephrolithiasis (kidney stones).
  • Pseudohypoparathyroidism or known hypersensitivity to the ingredients.

Conditional Use and Restrictions

Population/Condition Regulatory Status
Children under 12 years Not Recommended (Contraindicated for many standard formulations).
Pregnancy/Lactation Restricted (High-dose formulations are not recommended; overdose must be strictly avoided).
Sarcoidosis Use with caution (Requires close monitoring of calcium levels).

These official classifications strictly define the appropriate patient groups and conditions for Uprise-D3 use, ensuring consistency with established risk profiles.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Uprise-D3 (cholecalciferol) centers on substances that alter its absorption, metabolic clearance, or create additive pharmacodynamic risk. All documented interactions are based strictly on official government regulatory sources.

Medicinal Products Affecting Exposure

Certain medicines are officially documented to reduce the body's systemic exposure to cholecalciferol. This occurs through two primary mechanisms described in regulatory documents: reduced absorption in the gut, noted with substances such as bile-acid binding resins (e.g., Cholestyramine, Colestipol) and Orlistat; or increased metabolic clearance by the liver. The increased clearance is described with hepatic enzyme inducers including some anticonvulsants (e.g., Phenytoin) and Rifampicin, resulting in a documented reduction of cholecalciferol plasma concentration. Furthermore, Isoniazid and imidazole antifungal agents are noted to interfere with the final metabolic activation of the vitamin in the kidney.

Pharmacodynamic and Supplement Interactions

A documented constraint involves pharmacodynamic reinforcement. Co-administration with thiazide diuretics increases the official risk of hypercalcaemia due to their effect on reducing calcium excretion. Other official restrictions include combining Uprise-D3 with other Vitamin D forms or high-dose calcium/phosphate supplements, which carry a documented increased risk of toxicity. Co-administration with aluminum-containing antacids is documented to increase aluminum absorption. The medicine's absorption is officially stated to be enhanced when taken with fat-containing food.

Mechanism of Action

Uprise-D3, containing cholecalciferol (vitamin D3), functions as a pro-hormone that requires metabolic activation. Following systemic absorption, cholecalciferol undergoes C25-hydroxylation in the liver by cytochrome P450 enzymes (e.g., CYP2R1) to form calcifediol (25-hydroxyvitamin D3). Calcifediol subsequently travels to the kidneys for C1alpha-hydroxylation by the enzyme 1alpha-hydroxylase (CYP27B1), yielding the biologically active steroid hormone, calcitriol (1,25-dihydroxyvitamin D3).

Calcitriol acts as an agonist for the Vitamin D Receptor (VDR), a ligand-activated nuclear transcription factor belonging to the steroid hormone receptor superfamily. The activated calcitriol-VDR complex heterodimerizes with the Retinoid X Receptor (RXR) and translocates to the cell nucleus. This heterodimer binds to specific DNA sequences known as Vitamin D Response Elements (VDREs) in the promoter regions of target genes. This molecular interaction modulates gene transcription, leading to altered expression of proteins in target tissues.

Downstream consequences include the increased synthesis of calcium-transport proteins, such as calbindin, in intestinal epithelial cells, promoting the transmembrane flux of dietary calcium and phosphate. Furthermore, calcitriol acts on bone tissue cells and the renal tubules to systemically modulate calcium and phosphate reabsorption and mobilization, contributing to the maintenance of circulating mineral homeostasis.

Dosage and Administration Information

Uprise-D3, which contains cholecalciferol, is administered strictly by the oral route in various available forms, including capsules, tablets, and oral solutions. The usage protocol is generally divided into two phases. The initial regimen for treating a diagnosed deficiency involves a short-term course, often using doses ranging from 1,000 IU to 4,000 IU once daily or an intermittent schedule of 20,000 IU to 50,000 IU once weekly.

Following this correction phase, there is a long-term maintenance schedule, which typically requires 1,000 IU to 2,000 IU once daily to sustain adequate levels. For proper absorption, a key administration requirement is that the dose must be taken with the main meal of the day, as cholecalciferol is a fat-soluble substance. Solid forms must be swallowed whole and not crushed or chewed. Furthermore, effective use of the regimen requires the concurrent presence of dietary calcium.

Standard protocols include specific constraints for certain patient groups. The use of Uprise-D3 is not recommended in cases of severe renal impairment (GFR < 35 mL/min). Dosing for older adults requires caution, often beginning at the low end of the standard range. If a scheduled daily dose is missed, the dose should be taken as soon as remembered, but users must not take a double dose to compensate for the skipped one.

Recent Clinical Evidence

Research evidence / Overview of studies for Uprise-D3

The research evidence available for Uprise-D3 (cholecalciferol) was studied for individuals with diagnosed Vitamin D deficiency or insufficiency. The available evidence is extensive, relying on large-scale Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies monitored patients to track measurements in the key biological marker: the serum 25(OH)D concentration in the blood. Where Uprise-D3 was evaluated, data showed patterns related to measured increases in this concentration, which were consistently reported across many studies.

Studies on Skeletal Health and Fracture Risk

Uprise-D3 was studied for conditions characterized by low bone density and fragility fracture incidence. Research relies heavily on large-scale, long-term RCTs that monitor populations such as Older Adults and Postmenopausal Women. Studies observed that for patients with an established Vitamin D deficiency, research explored associated patterns related to fracture incidence. However, when research examined individuals who were not deficient at the start of the study, the observed patterns related to fracture incidence were described as less consistent.

Research on Osteomalacia and Rickets

Uprise-D3 was evaluated in studies exploring conditions associated with severely impaired bone mineralization, specifically Osteomalacia in adults and Rickets in children. Studies examined outcomes related to physical discomfort and functional imbalance, such as healing of bone lesions. The data for these conditions is limited by modest sample sizes, and there is limited information for long-term outcomes on recurrence.

Evidence on Musculoskeletal Symptoms

Research examined Uprise-D3's association with deficiency-related musculoskeletal symptoms, including generalized pain, muscle weakness, and fatigue. Findings reported on subjective outcomes, such as patient-reported pain and fatigue scales, were found to be highly heterogeneous across different studies. Research often monitors other influencing factors, making the certainty of findings low due to influencing factors.

Understanding Research Gaps and Uncertainty

A primary limitation noted by researchers is the heterogeneity across studies, meaning the methods, doses, and populations vary significantly. Findings were mixed in the large body of research that examined non-skeletal outcomes. Long-term effects for symptomatic relief are not fully established, as follow-up durations were often limited for those endpoints. Research provides context about group patterns, not personal outcomes.

Key Studies & References

  1. MedlinePlus: Cholecalciferol (Oral Route) Drug Information
  2. NICE Guideline [NG148]: Vitamin D deficiency in adults and children

Frequently Asked Questions (FAQ)

Common questions about Uprise-D3 (FAQ)

Q: Why is Uprise-D3 sometimes prescribed for bone health?

The active substance in Uprise-D3 is critical for regulating the absorption of calcium and phosphate from the diet. These minerals are foundational for maintaining skeletal integrity and supporting bone structure. Official information describes this regulatory action as key to supporting bone health.

Q: Is Uprise-D3 considered a medicine or a nutritional supplement?

The classification of cholecalciferol (the active ingredient) can depend on its strength and concentration, as well as local government regulations. Lower doses are often available as nutritional supplements, while high-dose formulations are typically classified and regulated as prescription-only medicines by government agencies.

Q: What are some of the known possible side effects of taking Uprise-D3?

According to official documentation, the most significant adverse reactions are uncommon and linked to elevated calcium levels, specifically hypercalcemia (high blood calcium) and hypercalciuria (high urinary calcium). Adverse reactions affecting the gastrointestinal system, such as nausea, vomiting, and constipation, are documented in official regulatory labeling.

Q: Is feeling nauseous or tired a common side effect of Uprise-D3?

Official labeling lists nausea as an adverse reaction affecting the gastrointestinal system. Although tiredness is not a commonly listed effect, muscle weakness is cited as a potential symptom of hypercalcemia, which is a key safety concern related to the medicine.

Q: Does official evidence discuss Uprise-D3's role in the immune system?

Research evidence has explored the active substance's role in immune function, noting its ability to stimulate immunogenic activity and support overall immune function. However, the available evidence on non-skeletal outcomes is generally described as mixed.

Q: Is Uprise-D3 known to be absorbed better with food?

Yes, official regulatory documents state that the medicine's absorption is enhanced when taken with food containing fat. For this reason, official instructions indicate that the dose should be taken with the main meal of the day.

Q: Do I need to have blood tests while using Uprise-D3?

Regulatory guidance indicates that patients with certain pre-existing conditions, such as sarcoidosis, require close monitoring of calcium levels. Furthermore, regulatory guidance indicates that regular monitoring of blood levels is recommended during long-term maintenance use.

Q: Do I need a prescription to get Uprise-D3?

The requirement for a prescription is dependent on the specific strength and formulation of the product, as well as local government regulations. High-dose cholecalciferol products are often classified as prescription medicines by government health agencies.

Q: Are there different strengths or versions of Uprise-D3 available?

Yes, Uprise-D3 is available in various official forms, including capsules, tablets, and oral solutions. Dosages prescribed for treatment and maintenance vary widely, ranging from daily amounts to intermittent high-dose amounts.

Q: Is Uprise-D3 intended to be used long-term?

The usage protocol is typically divided into an initial, short-term treatment course followed by a prescribed long-term maintenance schedule. This maintenance phase is intended to sustain adequate vitamin D levels over time.

Q: Can Uprise-D3 be taken with antacids?

Official warnings are documented for co-administration with aluminum-containing antacids due to the potential for increased aluminum absorption. Use with magnesium-containing antacids may also be restricted, particularly for individuals with reduced kidney function.

Q: Are there any common foods or drinks that might interact with Uprise-D3?

The medicine's absorption is positively enhanced when taken with fat-containing food. Some official guidance suggests that grapefruit and grapefruit juice may potentially alter the blood levels and effects of cholecalciferol.

Q: When should someone stop taking Uprise-D3 because of a side effect?

The medicine is formally contraindicated (should not be used) by individuals with existing signs of toxicity, such as confirmed hypercalcemia (high blood calcium). If serious signs of hypercalcemia or a severe allergic reaction occur, official guidance describes this as a situation that requires immediate medical attention.

Q: Where can I find the official prescribing information for Uprise-D3?

Official prescribing information, such as the Summary of Product Characteristics (SmPC) or the full drug label, can be accessed through the websites of government regulatory agencies. Examples include the FDA (DailyMed), EMA, MHRA, and Health Canada.

Q: Does Uprise-D3 contain lactose or gluten?

The product’s specific inactive ingredients (excipients), which may include substances like lactose or gluten, are formally detailed in the official drug label or Summary of Product Characteristics (SmPC). Users should review this information for the specific formulation they are taking.

Q: What ingredients are listed in Uprise-D3 besides the active one?

The ingredients other than the active substance (cholecalciferol) are known as excipients or inactive components. These are formally listed in the official drug label or product monograph under the section describing the full composition of the medicine.

Q: Is Uprise-D3 known to cause headaches?

Official regulatory adverse reaction tables do not typically list headache as a common or uncommon effect of therapeutic doses. However, headache is cited as a potential symptom of hypercalcemia (high blood calcium), which is a key safety concern.

Q: Can Uprise-D3 affect my blood pressure?

Uprise-D3 is officially documented to interact with thiazide diuretics (a class of blood pressure medicine), increasing the risk of hypercalcaemia. However, regulatory adverse reaction tables do not list changes in blood pressure as a standard side effect of the medicine itself.

Q: What is the maximum period of time Uprise-D3 is usually prescribed for?

Regulatory documents generally state that the optimal duration of use for cholecalciferol has not been definitively determined. Regulatory documents note that the need for continued, long-term therapy is subject to periodic re-evaluation by a healthcare professional.

Q: Are there specific patient groups that need special monitoring while using Uprise-D3?

Yes, patients with conditions such as sarcoidosis, severe renal impairment, and the elderly require specific monitoring and caution in dosing. Regular monitoring of calcium levels is generally advised during long-term use, according to regulatory guidance.

Q: How is Uprise-D3's purpose described in official health documents?

The core function is officially described as acting as an essential bodily regulator. Its main purpose is to manage the absorption of calcium and phosphate from the diet, which is described as foundational for supporting skeletal integrity and muscle function.

Q: Are there any known severe or rare side effects of Uprise-D3?

Yes, officially documented rare and severe adverse reactions are usually the consequences of profound and prolonged hypercalcemia. These risks include the potential for irreversible renal impairment or nephrocalcinosis. Rare reactions also include hypersensitivity (e.g., rash).

Q: Is it possible to develop a dependency on Uprise-D3?

For general use, cholecalciferol (Vitamin D3) is not classified as a habit-forming drug in official regulatory documents. The term 'dependency' in a clinical context is often related to a rare genetic disorder concerning the vitamin's metabolism.

Q: Can Uprise-D3 affect mood or sleep?

High blood calcium levels (hypercalcemia), which is a key safety concern with the medicine, may potentially manifest as symptoms like confusion. Regulatory adverse reaction tables do not typically list mood changes or sleep disruption as common side effects of therapeutic doses.

Q: Is Uprise-D3 used for preventing conditions or for treating them?

Official labeling states that Uprise-D3 is used for both the prevention and treatment of diagnosed vitamin D deficiency and conditions associated with inadequate vitamin D levels.

Q: Does Uprise-D3 interact with diuretics?

Official documents specifically list an interaction with thiazide diuretics. Co-administration is stated to increase the official risk of hypercalcaemia (high blood calcium) due to the diuretic's effect on reducing calcium excretion.

How should Uprise-D3 be stored and disposed of?

How to Store and Dispose of Uprise-D3

To maintain the stability of the cholecalciferol (Vitamin D3) component, Uprise-D3 must be stored strictly according to official regulatory requirements.

Storage Conditions

Requirement Official Instruction
Temperature Store at room temperature, typically below 25 C or 30 C.
Protection Keep in a cool and dry place, protected from direct light, heat, and moisture.
Prohibited The medicine must not be frozen.
Container Keep Uprise-D3 in its original, tightly closed container until use.
Child Safety Store medication out of the sight and reach of children.

Disposal

Unused or expired Uprise-D3 must be disposed of in accordance with local regulations for pharmaceutical waste. Patients should consult a pharmacist or local collection program for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Uprise-D3 found in:

A-Z Index: